Publications by authors named "W Kievit"
Background: The androgen receptor pathway inhibitors (ARPI), abiraterone acetate and enzalutamide, are commonly used in first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, early resistance to ARPI treatment occurs frequently. Traditionally, the response is evaluated 3-6 months after the start of treatment.
View Article and Find Full Text PDFBackground: There is no consensus regarding the indication for postoperative radiotherapy (PORT) for T1- and T2-classified squamous cell carcinoma (SCC) of the external auditory canal (EAC) even with negative surgical margins. This study aimed to evaluate whether PORT provides additional benefits for these cases.
Methods: We collected retrospective data from fourteen international hospitals, including resected pT1- and pT2-classified EAC SCC with negative surgical margins.
The economic impact of open lower limb fractures in the Netherlands: a cost-of-illness study.
Eur J Trauma Emerg Surg
October 2024
Purpose: To estimate the one-year sum of direct costs related to open lower limb fracture treatment in an academic setting in the Netherlands. The secondary objective was to estimate the impact of deep infection and nonunion on one-year total direct costs.
Methods: A multi-center, retrospective cost analysis of open lower limb fractures treated in an academic setting in the Netherlands, between 1 January 2017 and 31 December 2018, was conducted.
Objective: To assess the effect of wait and scan (W&S) and stereotactic radiosurgery (SRS) on health-related quality of life (HRQoL) over time in patients with a stable vestibular schwannoma (VS) and growing VS.
Study Design: Longitudinal, multicenter, observational study.
Setting: Tertiary expert center for VS (Radboudumc Nijmegen) and Gamma-Knife center ETZ Hospital Tilburg.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
Dig Dis Sci
June 2024
Article Synopsis
- In the LADI trial, researchers found that extending adalimumab (ADA) dosing intervals was just as effective as standard dosing for Crohn's disease patients in remission.
- The study aimed to create a prediction model to identify patients who could successfully increase their dosing intervals based on trial data.
- Results showed that 60.6% of patients successfully extended their dosing, with certain factors (like smoking and prior surgeries) making success less likely; the model's effectiveness needs further external validation before clinical use.